Koech, A;
Omuse, G;
Mugo, AG;
Mwaniki, IG;
Mutunga, JM;
Mukhanya, MW;
Wanje, O;
Mwashigadi, GM;
Katana, GG;
Craik, R;
et al.
Koech, A; Omuse, G; Mugo, AG; Mwaniki, IG; Mutunga, JM; Mukhanya, MW; Wanje, O; Mwashigadi, GM; Katana, GG; Craik, R; von Dadelszen, P; Le Doare, K; Temmerman, M
(2023)
SARS-CoV-2 seroprevalence in pregnant women in Kilifi, Kenya from March 2020 to March 2022.
FRONTIERS IN PUBLIC HEALTH, 11.
p. 1292932.
ISSN 2296-2565
https://doi.org/10.3389/fpubh.2023.1292932
SGUL Authors: Le Doare, Kirsty
Abstract
Background: Seroprevalence studies are an alternative approach to estimating the extent of transmission of SARS-CoV-2 and the evolution of the pandemic in different geographical settings. We aimed to determine the SARS-CoV-2 seroprevalence from March 2020 to March 2022 in a rural and urban setting in Kilifi County, Kenya.
Methods: We obtained representative random samples of stored serum from a pregnancy cohort study for the period March 2020 to March 2022 and tested for antibodies against the spike protein using a qualitative SARS-CoV-2 ELISA kit (Wantai, total antibodies). All positive samples were retested for anti-SARS-CoV-2 anti-nucleocapsid antibodies (Euroimmun, ELISA kits, NCP, qualitative, IgG) and anti-spike protein antibodies (Euroimmun, ELISA kits, QuantiVac; quantitative, IgG).
Results: A total of 2,495 (of 4,703 available) samples were tested. There was an overall trend of increasing seropositivity from a low of 0% [95% CI 0–0.06] in March 2020 to a high of 89.4% [95% CI 83.36–93.82] in Feb 2022. Of the Wantai test-positive samples, 59.7% [95% CI 57.06–62.34] tested positive by the Euroimmun anti-SARS-CoV-2 NCP test and 37.4% [95% CI 34.83–40.04] tested positive by the Euroimmun anti-SARS-CoV-2 QuantiVac test. No differences were observed between the urban and rural hospital but villages adjacent to the major highway traversing the study area had a higher seroprevalence.
Conclusion: Anti-SARS-CoV-2 seroprevalence rose rapidly, with most of the population exposed to SARS-CoV-2 within 23 months of the first cases. The high cumulative seroprevalence suggests greater population exposure to SARS-CoV-2 than that reported from surveillance data.
Item Type: |
Article
|
Additional Information: |
Copyright © 2023 Koech, Omuse, Mugo, Mwaniki, Mutunga, Mukhanya, Wanje, Mwashigadi, Katana, Craik, von Dadelszen, Le Doare, Temmerman, periCOVID-Africa and The PRECISE Network. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
Keywords: |
SARS-CoV-2, COVID-19, seroprevalence, pregnancy, Kenya, antibodies, 1117 Public Health and Health Services |
SGUL Research Institute / Research Centre: |
Academic Structure > Infection and Immunity Research Institute (INII) |
Journal or Publication Title: |
FRONTIERS IN PUBLIC HEALTH |
ISSN: |
2296-2565 |
Dates: |
Date | Event |
---|
19 December 2023 | Published | 20 November 2023 | Accepted |
|
Publisher License: |
Creative Commons: Attribution 4.0 |
Projects: |
|
Web of Science ID: |
WOS:001134330500001 |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/115997 |
Publisher's version: |
https://doi.org/10.3389/fpubh.2023.1292932 |
Statistics
Item downloaded times since 12 Jan 2024.
Actions (login required)
![Edit Item](/style/images/action_view.png) |
Edit Item |